Table 2.

The concentrations at which 50 and 90 % of infections are prevented under the various conditions of copper phthalocyanine sulfate (CuPcS) exposure: HIV pre-treated with CuPcS; peripheral blood mononuclear cells (PBMC) pre-treated with CuPcS; simultaneous addition of HIV, PBMCs, and CuPcS; and pre-incubation of HIV and PBMCs with subsequent addition of CuPcS

CuPcS Inhibition of HIV-1BAL Infection of PBMCs
	EC50 μg/ml	EC90 μg/ml
HIV pre-treated	53.31	184.7
PBMCs pre-treated	42.96	147.2
CuPcS added post-infection	26.11	215.3
Combined addition	54.72	186.7
Pre (100 μg/mL)- and post-treatment	Undefined	Undefined